Please Wait
Applying Filters...
menu
    • menu
    Aucta Pharmaceuticals-PSE
    News
    Aucta Pharma prepares for the launch of PYQUVI Suspension

    06 Feb 2026

    // PR NEWSWIRE

    Aucta’s Generics Pyquvi Receives Approval in US

    30 Jun 2025

    // FDA

    Aucta`s Generics Arformoterol Receives Approval in US

    03 Feb 2025

    // FDA

    DATA COMPILATION
    #PharmaFlow

    Aucta Read More

    Contact Supplier

    Website

    IPhEB Russia

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/excipient-market-overview-clariant-sets-up-its-first-peg-excipients-facility-in-us-india-harmonizes-22-excipient-monographs
    Left Arrow
    Right Arrow

    Aucta is a global brand that creates better products from proven molecules.

    Related CompaniesRelated Companies

    About

    Aucta Pharmaceuticals is an emerging drug product development company focusing on new branded 505(b)(2) products and technology platform-based niche generics. Aucta adopts a branded/generic hybrid model, generating both near-term product revenue and mid- to long-term investment return, aiming to become a significant specialty pharma player in the United States and China marketplace. We focus on developing enhanced products for patients with a therapeutic focus on CNS disorders, as well as Ophthalmics, and Inhalation therapies.
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.